Research analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a research note issued on Saturday. The firm set a “hold” rating on the stock.
A number of other research analysts have also recently issued reports on the company. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of DBV Technologies in a report on Thursday, August 1st.
Get Our Latest Research Report on DBVT
DBV Technologies Stock Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.42 million. During the same quarter in the previous year, the company earned ($0.26) earnings per share. On average, equities research analysts predict that DBV Technologies will post -1.43 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) by 6.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 71.74% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Further Reading
- Five stocks we like better than DBV Technologies
- What Is WallStreetBets and What Stocks Are They Targeting?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- How to buy stock: A step-by-step guide for beginners
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.